 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- DSB1559 / Duke Street Bio
Investigating PARP1 selective inhibitor DSB1559 efficacy in BRCA1-associated triple negative breast cancer (Section 22) - Mar 5, 2024 - Abstract #AACR2024AACR_9350;
DSB1559 is a novel and potent PARP1 inhibitor which has superior selectivity for PARP1 compared to Olaparib and PARP1i AZD5305. Taken together, DSB1559 is a highly selective PARP1 inhibitor that demonstrates superior efficacy compared to Olaparib in a BRCA1-associated immune-competent TNBC model.